2010至2019年中国三级医疗中心极早产儿死亡与并发症情况
该回顾性队列研究纳入2010年1月1日至2019年12月31日中国31个省68个新生儿重症监护病房出院的胎龄小于28周极早产儿8514例,随访至出院,主要终点为出院存活和严重并发症(支气管肺发育不良、III-IV级脑室内出血、白质损伤、II-III期坏死性小肠结肠炎、脓毒症或严重早产儿视网膜病变)。总体出院存活率62.3%,随胎龄增加由22周4.8%升至27周69.1%。24至27周存活率由2010年56.4%(95%CI 50.1%-62.7%)升至2019年68.0%(95%CI 65.7%-70.2%),平均差11.5%(95%CI 4.9%-18.2%,P<.001);小于24周无显著变化。严重并发症总发生率72.4%,由2010年52.0%(95%CI 45.4%-58.6%)升至2019年82.3%(95%CI 80.5%-84.1%),平均差30.3%(95%CI 23.5%-37.1%,P<.001)。作者认为需要更积极有效的治疗策略,尤其针对胎龄25至27周者。
要点
- 总体8514例极早产儿出院存活率62.3%,各胎龄存活率:22周1/21(4.8%)、23周13/71(18.3%)、24周144/408(35.3%)、25周480/987(48.6%)、26周1423/2331(61.0%)、27周3241/4692(69.1%)。
- 24至27周存活率由2010年56.4%(95%CI 50.1%-62.7%)升至2019年68.0%(95%CI 65.7%-70.2%),平均差11.5%(95%CI 4.9%-18.2%,P<.001);小于24周无显著变化。
- 严重并发症总发生率72.4%,由2010年52.0%(95%CI 45.4%-58.6%)升至2019年82.3%(95%CI 80.5%-84.1%),平均差30.3%(95%CI 23.5%-37.1%,P<.001)。
- 地区存活率差异近2倍(1.94倍;95%CI 1.66-2.27;P<.001),西北地区39.7% vs 华北地区76.9%。
- 多因素分析中胎龄(aRR 1.084;95%CI 1.063-1.105;P<.001)、出生体重(aRR 1.028;95%CI 1.020-1.036;P<.001)、胎膜早破(aRR 1.025;95%CI 1.002-1.048;P=.03)、产前使用类固醇(aRR 1.029;95%CI 1.004-1.055;P=.02)与存活改善相关。
适用人群与场景
- 纳入标准:2010年1月1日至2019年12月31日中国31个省68个新生儿重症监护病房出院、胎龄小于28周的极早产儿,共8514例;其中男性5295例(62.2%),小于胎龄儿116例(2.0%)。
- 场景:三级医疗中心新生儿重症监护病房出院时点,非急诊或成人ICU场景。
研究设计与关键结果
- 研究设计:回顾性队列研究,数据来自2010年1月1日至2019年12月31日中国31个省68个新生儿重症监护病房,分析时间为2020年8月至10月。
- 主要终点:出院存活率62.3%(5302/8514);严重并发症(支气管肺发育不良、III-IV级脑室内出血、白质损伤、II-III期坏死性小肠结肠炎、脓毒症或严重早产儿视网膜病变)发生率72.4%(5999/8281)。
- 按胎龄出院存活率:22周4.8%(1/21)、23周18.3%(13/71)、24周35.3%(144/408)、25周48.6%(480/987)、26周61.0%(1423/2331)、27周69.1%(3241/4692)。
- 24至27周存活率由2010年56.4%(136/241;95%CI 50.1%-62.7%)升至2019年68.0%(1110/1633;95%CI 65.7%-70.2%),平均差11.5%(95%CI 4.9%-18.2%;P<.001);小于24周无显著变化。
- 严重并发症率由2010年52.0%(116/223;95%CI 45.4%-58.6%)升至2019年82.3%(1363/1656;95%CI 80.5%-84.1%),平均差30.3%(95%CI 23.5%-37.1%;P<.001)。
- 地区存活率:西北地区39.7%(188/474)vs 华北地区76.9%(887/1153),相差1.94倍(95%CI 1.66-2.27;P<.001)。
- 与存活改善相关的因素:胎龄(aRR 1.084;95%CI 1.063-1.105;P<.001)、出生体重(aRR 1.028;95%CI 1.020-1.036;P<.001)、胎膜早破(aRR 1.025;95%CI 1.002-1.048;P=.03)、产前类固醇(aRR 1.029;95%CI 1.004-1.055;P=.02)。
- 与存活降低相关的因素:小于胎龄儿(aRR 0.801;95%CI 0.679-0.945;P=.01)、男性(aRR 0.975;95%CI 0.954-0.997;P=.02)、多胎(aRR 0.955;95%CI 0.929-0.982;P=.001)、母亲妊娠期糖尿病(aRR 0.946;95%CI 0.913-0.981;P=.002)、低Apgar评分(aRR 0.951;95%CI 0.925-0.977;P<.001)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 研究提示中国极早产儿总体死亡与并发症风险较高,出院存活率随时间改善但严重并发症率上升;作者认为需要更积极有效的治疗策略,尤其针对胎龄25至27周者。
- 多因素分析显示产前使用类固醇与存活改善相关(aRR 1.029;95%CI 1.004-1.055;P=.02),但原文未给出剂量或疗程推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Extreme prematurity is associated with a substantial burden on health care systems worldwide. However, little is known about the prognosis of infants born extremely preterm in developing countries, such as China.
OBJECTIVE: To describe survival and major morbidity among infants born extremely preterm in China over the past decade.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was conducted from January 1, 2010, through December 31, 2019. Included individuals were infants with gestational age less than 28 weeks discharged from 1 of 68 neonatal intensive care units located in 31 provinces in China. Data were analyzed from August through October 2020.
EXPOSURE: Extremely preterm birth.
MAIN OUTCOMES AND MEASURES: Survival to discharge and major morbidity (ie, bronchopulmonary dysplasia, grades III-IV intraventricular hemorrhage, white matter injury, stage II-III necrotizing enterocolitis, sepsis, or severe retinopathy of prematurity) were measured.
RESULTS: Among 8514 eligible infants, 5295 (62.2%) were male and 116 infants (2.0%) were small for gestational age (SGA). Overall, 5302 infants (62.3%) survived to discharge. The survival rate was 1 of 21 infants (4.8%) at 22 weeks, 13 of 71 infants (18.3%) at 23 weeks, 144 of 408 infants (35.3%) at 24 weeks, 480 of 987 infants (48.6%) at 25 weeks, 1423 of 2331 infants (61.0%) at 26 weeks, and 3241 of 4692 infants (69.1%) at 27 weeks. Survival increased from 136 of 241 infants (56.4%; 95% CI, 50.1%-62.7%) in 2010 to 1110 of 1633 infants (68.0%; 95% CI, 65.7%-70.2%) in 2019 for infants born at 24 to 27 weeks (mean difference, 11.5%; 95% CI, 4.9%-18.2%; P < .001), without a significant change for infants born at less than 24 weeks. Major morbidity was found in 5999 of 8281 infants overall, for a rate of 72.4%, which increased from 116 of 223 infants (52.0%; 95% CI, 45.4%-58.6%) to 1363 of 1656 infants (82.3%; 95% CI, 80.5%-84.1%) from 2010 to 2019 (mean difference, 30.3%; 95% CI, 23.5%-37.1%, P < .001). Regional variations in survival were identified, with an almost 2-fold increase (1.94-fold; 95% CI, 1.66-2.27; P < .001) from 188 of 474 infants (39.7%) in northwest China to 887 of 1153 infants (76.9%) in north China. Gestational age (adjusted risk ratio [aRR], 1.084; 95% CI, 1.063-1.105; P < .001), birth weight (aRR, 1.028; 95% CI, 1.020-1.036; P < .001), premature rupture of membranes (aRR, 1.025; 95% CI, 1.002-1.048; P = .03), and antenatal steroids (aRR, 1.029; 95% CI, 1.004-1.055; P = .02) were associated with improved survival, while being born SGA (aRR, 0.801; 95% CI, 0.679-0.945; P = .01), being male (aRR, 0.975; 95% CI, 0.954-0.997; P = .02), multiple birth (aRR, 0.955; 95% CI, 0.929-0.982; P = .001), having a mother with gestational diabetes (aRR, 0.946; 95% CI, 0.913-0.981; P = .002), and low Apgar score (aRR, 0.951; 95% CI, 0.925-0.977; P < .001) were found to be risk factors associated with decreased chances of survival.
CONCLUSIONS AND RELEVANCE: This study found that infants born extremely preterm were at increased risk of mortality and morbidity in China, with a survival rate that improved over time and a major morbidity rate that increased. These findings suggest that more active and effective treatment strategies are needed, especially for infants born at gestational age 25 to 27 weeks.
参考来源
- Zhu Z, Yuan L, Wang J, et al. Mortality and Morbidity of Infants Born Extremely Preterm at Tertiary Medical Centers in China From 2010 to 2019. JAMA Netw Open. 2021. PMID: 33974055. doi:10.1001/jamanetworkopen.2021.9382
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。